Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ As Biomarkers of Cancer in Cancer-associated Anti-TIF1-γ Antibody-positive Dermatomyositis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2022 Nov 10

PMID 36357631

Authors

Xiaomeng Li

Yuan Huang

Yongmei Liu

Songxin Yan

Liubing Li

Linlin Cheng

Haolong Li

Haoting Zhan

Fengchun Zhang

Yongzhe Li

Affiliations

Soon will be listed here.

Abstract

Objectives: The objective of the current study was to detect plasma profiles of inflammatory cytokines for determining potential biomarkers indicating cancer presence among the anti-TIF1-γ antibody-positive dermatomyositis (DM) patients.

Methods: Twenty-seven cancer-associated anti-TIF1-γ antibody-positive DM (Cancer TIF1-γ-DM) patients were compared with 20 anti-TIF1-γ antibody-positive DM patients without cancer (Non-cancer TIF1-γ-DM) and 10 healthy controls (HC). The plasma levels of 17 cytokines were determined using the Luminex 200 system. The ability of plasma VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ levels to distinguish the presence of cancer was evaluated through the area under the curve (AUC) analysis. Potential protein interactions of TIF1-γ and the five cytokines were analyzed using the STRING database.

Results: VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ plasma levels were significantly higher in the Cancer TIF1-γ-DM group, especially those without any anticancer treatment, than those in the non-cancer TIF1-γ-DM and HC groups. Meanwhile, anti-TIF1-γ antibody and the five cytokines could distinguish cancer presence in anti-TIF1-γ antibody-positive DM patients. The STRING network indicated that TIF1-γ potentially interacted with the cytokines. Positive correlations of VEGF-A among CCL2, IL-6, and IFN-γ and between IFN-γ and IL-6 were observed in Cancer TIF1-γ-DM patients. VEGF-A, TNF-α, CCL2, and IL-6 were positively associated with muscle-associated enzymes among the Cancer TIF1-γ-DM patients.

Conclusion: The present study identified VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as significant potential biomarkers indicating the presence of cancer and demonstrated a more detailed cytokine profile during diagnosis. These biomarkers could provide better screening strategies and insight into the Cancer TIF1-γ-DM pathogenesis. Key Points • VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ are potential biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Potential pathogenic molecular mechanism of the cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.

Citing Articles

Increased Cytokine Levels in Seronegative Myositis: Potential Th17 Immune Response Implications.

Aguilar-Vazquez A, Chavarria-Avila E, Gutierrez-Hernandez J, Toriz-Gonzalez G, Salazar-Paramo M, Medrano-Ramirez G Int J Mol Sci. 2024; 25(20).

PMID: 39456842 PMC: 11508411. DOI: 10.3390/ijms252011061.

Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary Biliary Cholangitis.

Bauer A, Rawa T Int J Mol Sci. 2024; 25(2).

PMID: 38279333 PMC: 10816849. DOI: 10.3390/ijms25021333.

References

DeWane M, Waldman R, Lu J . Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2019; 82(2):267-281. DOI: 10.1016/j.jaad.2019.06.1309. View

Lundberg I, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L . Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021; 7(1):86. DOI: 10.1038/s41572-021-00321-x. View

Qiang J, Kim W, Baibergenova A, Alhusayen R . Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2016; 21(2):131-136. DOI: 10.1177/1203475416665601. View

Hill C, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A . Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357(9250):96-100. DOI: 10.1016/S0140-6736(00)03540-6. View

Trallero-Araguas E, Rodrigo-Pendas J, Selva-OCallaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M . Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2011; 64(2):523-32. DOI: 10.1002/art.33379. View

Gono T, Kuwana M . Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Rev Clin Immunol. 2019; 16(1):79-89. DOI: 10.1080/1744666X.2019.1699059. View

Li S, Ge Y, Yang H, Wang T, Zheng X, Peng Q . The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Clin Rheumatol. 2019; 38(8):2171-2179. DOI: 10.1007/s10067-019-04503-7. View

Cerezo L, Vencovsky J, Senolt L . Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. Curr Opin Rheumatol. 2020; 32(6):534-541. DOI: 10.1097/BOR.0000000000000744. View

Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

10.

Zhao Q, Chen Y, Diao L, Zhang S, Wu D, Xue F . Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody. Rheumatology (Oxford). 2021; 61(5):2176-2184. DOI: 10.1093/rheumatology/keab625. View

11.

Tabrez S, Jabir N, Imran Khan M, Khan M, Shakil S, Siddiqui A . Association of autoimmunity and cancer: An emphasis on proteolytic enzymes. Semin Cancer Biol. 2019; 64:19-28. DOI: 10.1016/j.semcancer.2019.05.006. View

12.

Cordel N, Derambure C, Coutant S, Mariette X, Jullien D, Debarbieux S . TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis. Rheumatology (Oxford). 2021; 60(12):5863-5867. DOI: 10.1093/rheumatology/keab260. View

13.

Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez M, Milisenda J . Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2017; 57(2):388-396. PMC: 5850766. DOI: 10.1093/rheumatology/kex413. View

14.

Ly N, Ma N, Ueda-Hayakawa I, Nguyen C, Anada R, Okamoto H . Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies. J Dermatol Sci. 2021; 104(3):177-184. DOI: 10.1016/j.jdermsci.2021.10.003. View

15.

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

16.

Bohan A, Peter J . Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8):403-7. DOI: 10.1056/NEJM197502202920807. View

17.

Lundberg I, Tjarnlund A, Bottai M, Werth V, Pilkington C, de Visser M . 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017; 76(12):1955-1964. PMC: 5736307. DOI: 10.1136/annrheumdis-2017-211468. View

18.

Chinoy H, Fertig N, Oddis C, Ollier W, Cooper R . The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007; 66(10):1345-9. PMC: 1994304. DOI: 10.1136/ard.2006.068502. View

19.

Selva-OCallaghan A, Martinez-Gomez X, Trallero-Araguas E, Pinal-Fernandez I . The diagnostic work-up of cancer-associated myositis. Curr Opin Rheumatol. 2018; 30(6):630-636. PMC: 11611047. DOI: 10.1097/BOR.0000000000000535. View

20.

Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T . Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis. J Dermatol. 2020; 47(5):490-496. DOI: 10.1111/1346-8138.15284. View